


The CPE Brief

July 2026

Tailored Insights for You



AriBio Completes Phase 3 Trial of AR1001 in Early Alzheimer's Disease

AriBio completed dosing in the global Phase 3 POLARIS-AD trial of AR1001, an investigational oral therapy for early Alzheimer's disease. The upcoming readout will provide important data on the potential of a convenient, disease-modifying treatment approach beyond current amyloid-targeted therapies.

[Read the Press Release](#)

AC Immune Reports ACI-24 Data in Early Alzheimer's Disease

Interim Phase 1b/2 ABATE data showed ACI-24 was generally well tolerated with anti-amyloid antibody responses in patients with prodromal Alzheimer's disease, supporting continued development of active immunotherapy approaches.

[Learn More](#)



Alzheimer's Association Expands Dementia Respite Care Initiative

The Alzheimer's Association awarded nearly \$4 million in grants to expand community-based respite care programs for people living with dementia and their caregivers, highlighting the growing focus on caregiver support as a key component of comprehensive Alzheimer's care.

[Read More](#)

Upcoming Alzheimer's Research Highlights at AAIC 2026

AAIC 2026 will feature new research presentations from across the Alzheimer's field, with updates expected across therapeutics, biomarkers, diagnostics, and clinical care strategies.

[Learn More](#)

Alzheimer's progress continues across therapeutic innovation and patient support, with emerging disease-modifying approaches, expanded caregiver resources, and new research updates anticipated at AAIC 2026.

CPE Spotlight



Our new website is live!

- Explore our capabilities across medical communications, including scientific content, stakeholder engagement, and education
- Discover how CPE helps transform complex science into meaningful conversations with healthcare audiences

[Visit us at cpeducate.com](#)

Below is a list of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

+ Medical Affairs

Asynchronous Engagements
KOL Identification & Contracting
MOA Visualization
MSL Training
Patient Education
Poster Presentations
Scientific Platform Development

Medical Affairs + Marketing

Advisory Boards
(Virtual or In-Person)
Conference Planning
Content Development
Core Slide Decks
KOL Engagements
Publications

Marketing

Branding & Visual Aids
Healthcare Event Production Management
Launch Preparation
Product Theater Planning & Logistics
Speaker Bureau Services
Speaker Training
Technical Productions

We launched our new website to provide a clearer view of CPE's capabilities, expertise, and approach to medical communications.

As you're planning upcoming initiatives, we'd welcome the opportunity to learn more about your priorities and discuss how CPE can support your team. Reply to this email and let's find a time to connect.

[Visit us at cpeducate.com](#)

With appreciation,

Allison Goldberg, MPA
Associate Vice President
CPE Communications
Cell: 917-509-9583
agoldberg@cpeducate.com

When you're ready to explore how the CPE Communications Team can support your company, contact Allison at agoldberg@cpeducate.com

CPE
Communications

